Program report · filed November 17, 2026
Sales TechniqueMeasured report
Mark Cuban: Founders Who Stop Selling Are the Ones Who Fail
Mark Cuban says the most common 'Shark Tank' founder mistake is not acting as the company's No. 1 salesperson: 'Sales cures all, and it's your responsibility.'
By Rebecca Stone3 min read513 words
Program notes
- Mark Cuban says the most common 'Shark Tank' founder mistake is 'not being the No. 1 salesperson.'
- He repeated three words of advice on the show: 'Sales cures all.'
- Cuban appeared as a main 'Shark Tank' investor for more than a decade before leaving the regular panel in 2025.
- He made the remarks on Scott Galloway's 'The Prof G Pod' in an episode aired Monday.
- Cuban now focuses on ventures including Cost Plus Drugs, aimed at lowering prescription drug prices.

Mark Cuban spent more than a decade on the "Shark Tank" panel, and he says the most common mistake entrepreneurs brought into the tank was refusing to act as their own top salesperson. "I think probably the most common is not being the No. 1 salesperson," the billionaire told Scott Galloway in Monday's episode of "The Prof G Pod."
Cuban left the show's regular panel last year. His verdict rests on a pattern he watched across years of early-stage pitches: founders of small companies arrive believing a celebrity investor will solve their revenue problem for them.
What did Cuban tell founders instead?
He repeated three words to entrepreneurs on the show: "Sales cures all." Because the pitching companies were "relatively small," Cuban said, founders often came in "thinking that a shark was going to be a silver bullet," or asking how to hire someone to lift their sales numbers.
Cuban rejected both instincts. The founder, he argued, holds an informational advantage no hire or investor can match at the start.
"When you're getting started, it's your baby, and you understand better than anybody what it's going to take to make this company successful," Cuban said. "But if it's your product or service and you aren't so excited about it that you want to be telling everybody and selling it to everybody, and helping people with that product or service, you're not going to be successful."
The claim carries a specific weight for teams under roughly a dozen people, where the founder remains the product's most informed advocate and no sales infrastructure exists yet.
Can an investor replace the founder in the sales role?
Cuban drew a hard line between what a "Shark Tank" deal delivers and what it cannot. A deal supplies cash, publicity, and an experienced partner. It does not persuade a single customer that the product is worth buying.
"I would tell entrepreneurs all the time, sales cures all, and it's your responsibility. If you don't take that responsibility, you're going to fail," he said.
Galloway agreed and widened the frame beyond customer deals. "Entrepreneur," he said, is effectively "a synonym for salesperson." His version of the job spans three audiences:
- Selling employees on joining
- Selling capital on investing
- Selling customers on buying
His fallback position matched Cuban's severity: "And if you can't sell, you need to partner with someone who can sell."
The two positions differ in one respect. Cuban assigns the responsibility to the founder personally. Galloway allows an escape route through a co-founder who can carry the sales function. Both agree the function cannot go unowned.
What is Cuban doing now?
After leaving the regular panel last year, Cuban has concentrated on ventures including Cost Plus Drugs, the company he founded to lower the price of prescription drugs. His commentary now arrives from outside the tank, but the operating rule he sold founders on for over a decade has not changed: revenue is the founder's job until the founder proves otherwise.
via feeds.businessinsider.com (Source)
More from Rebecca Stone
Show full bio
Market editor covering people, launches and day-to-day practice in Sales technique and methodology, sales enablement at Quota Brief.
139 articles
Also rated
- Founders, Not Sales, Block the Path Past $10 Million
- Smartly Founder Raises $10M for Zero Technologies' AI Sales Agent
- Abstract lands first CRO after $25M raise at 3x valuation
- SaaStr's Lemkin: Hire 1-2 Ex-Founders in 2027 to Carry the Load
- Martech Stacks Still Can't Prove Revenue Impact, and the Numbers Show Why